The president has signed an executive order that says the use of the Foreign Corrupt Practices Act has hurt American ...
Emblaveo (aztreonam-avibactam) was approved for treating complicated intra-abdominal infections with limited or no treatment options.
On Friday, the U.S. Judicial Panel on Multidistrict Litigation ordered nearly 70 lawsuits be coordinated beefore U.S.
U.K.-based ad agency DAIVID said Pfizer had a strong, positive message with its ad and scored high with intense positive emotions. The commercial was also a top performer with spikes in positive ...
Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...
In a move to position itself as a Pan-African pharmaceutical leader, Neimeth International Pharmaceuticals is targeting the ...
Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.
Pfizer’s contributions to animal health date back several decades, during which the company played a significant role in ...
System1's Test Your Ad data reveals the ads consumers liked best NEW YORK, Feb. 10, 2025 /PRNewswire/ -- System1, The ...
The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback